This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Genomic Health Announces Presentation Of New Data Further Supporting Use Of Oncotype DXA® In Europe

REDWOOD CITY, Calif., March 19, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9 th European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom.  New data will include an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX will also be presented at the meeting.

"Over the past decade, we have generated more clinical evidence than any company in the world around genomics in breast cancer, and the unmatched body of support specifically for the use of the Oncotype DX breast cancer test is highlighted in the EBCC presentations," said Christer Svedman, M.D., senior director of medical affairs in Europe, Genomic Health. "We will continue to apply world-class science to lead the translation of massive amounts of genomic data into practice-changing results to achieve better standards in treatment planning in breast cancer worldwide."

Physician Survey Reveals Substantial Differences in Chemotherapy Treatment Recommendations, Underscoring the Need for Broader Genomic Testing in Europe to Enable More Informed Decisions

Estrogen receptor (ER) positive breast cancer patients receive hormonal treatment after surgery, but sometimes chemotherapy is also needed. The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey[i] aims to identify the role of classic pathology criteria that clinicians use in daily practice when recommending adjuvant chemotherapy in ER positive patients.  This online survey analyzed responses from 911 physicians representing 52 countries. The results reveal substantial heterogeneity in the criteria used to determine chemotherapy use, suggesting a compelling need for broader use of objective, predictive genomic tests which can help physicians and patients make more informed treatment decisions.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs